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The unprecedented effort to identify one or more safe and 
effective vaccines for COVID-19 includes more than 180 can-
didates in development (1), with at least 12 in phase 3 trials 
(2). The testing of so many vaccine candidates, in a pandemic 
of a disease for which there are to date limited treatment op-
tions, raises a critical challenge: What should researchers do 
if a vaccine candidate is judged to be safe and efficacious? 
Guidance from the U.S. Food and Drug Administration (FDA) 
states that in the event that a COVID-19 vaccine candidate is 
judged to be “safe and effective,” discussion may be necessary 
“to address ethical arguments to break the blind and offer 
vaccine to placebo recipients” (3). We consider here two ques-
tions raised by this guidance: First, if a vaccine candidate is 
found to be safe and efficacious in a placebo-controlled trial, 
should the researchers continue that trial as designed? Sec-
ond, should researchers continue to test other vaccine candi-
dates using placebo-controlled trials? These two questions 
are especially timely given recent announcements by Pfizer 
and Moderna that their vaccine candidates have been found 
to be efficacious in preventing symptomatic COVID-19 (4, 5). 
VACCINE SAFETY AND EFFICACY 
A finding of efficacy occurs when a vaccine candidate being 
tested in a phase 3 trial meets its efficacy end point, either 
during an interim analysis or after study completion. The pri-
mary efficacy end point of current phase 3 trials is whether 
the vaccine candidate prevents symptomatic COVID-19 in in-
dividuals newly infected with severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) (6). A finding of efficacy 
in these trials thus implies that the vaccine candidate pro-
tects infected individuals from experiencing symptoms. A 
finding of safety occurs when there is sufficient data on the 
impact of the vaccine candidate to conclude that its potential 
benefits justify its risks in the target population. 
A single finding of safety and efficacy may not be suffi-
cient for a vaccine candidate to receive FDA approval. De-
pending on the strength of the data, it may be important to 
conduct additional research to learn more about the vaccine 
candidate and gain greater confidence in its safety and 
efficacy before offering it to millions of people. For example, 
the FDA frequently requires a finding of efficacy in two 
phase 3 trials before approving medical interventions for 
marketing to the public. 
Still, a finding of safety and efficacy in a phase 3 trial is 
an ethically critical point in the vaccine development process. 
From that point, receiving the vaccine candidate is known to 
offer protection to many individuals. Hence, receiving a pla-
cebo instead is contrary to their interests, even though it may 
be necessary to collecting socially valuable data. 
This tension between protecting research participants 
and gathering data that may benefit others is common to 
clinical research, and there is substantial literature on how to 
address it (7). Although this literature applies to the ethics of 
vaccine trials, the present situation is unparalleled. 
There is a global crisis for which there are currently lim-
ited treatment options. Hence, billions of individuals could 
benefit from a safe and efficacious vaccine. And having so 
many vaccine candidates in development substantially in-
creases the chances that one or more will be found to be safe 
and efficacious while others are still being tested. Limitations 
on current treatment options mean that it is in each individ-
ual’s interests to receive the first vaccine found to be safe and 
efficacious, rather than participate in vaccine trials where 
they might receive placebo or an unproven vaccine candidate. 
In addition, given the challenges of manufacturing suffi-
cient supply for so many people, and given that different vac-
cine candidates may be efficacious in different populations, 
several vaccines may be needed to meet the global need. This 
highlights the potential social value of conducting additional 
trials after one or more vaccine candidates are found to be 
safe and efficacious. 
Moreover, vaccine candidates typically have not been 
widely available until after they receive marketing approval 
by the FDA. However, the FDA has indicated that it may take 
the unprecedented step of making a vaccine candidate that is 
found to be safe and efficacious widely available through an 
emergency use authorization (EUA) before marketing ap-
proval. An EUA involves the FDA commissioner allowing 
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unapproved medical products to be used in an emergency to 
diagnose, treat, or prevent serious or life-threatening diseases 
or conditions “when there are no adequate, approved, and 
available alternatives” (8). 
PARTICIPANTS, NOT PATIENTS 
Pfizer recently announced that at the first interim analysis, 
its vaccine candidate was found to be 95% effective at pre-
venting symptomatic COVID-19 (4, 5). A week later, Moderna 
announced that its vaccine candidate was found to be 94.5% 
effective. At that point, the trials had enrolled more than 
43,000 and 30,000 participants, respectively, of whom 94 and 
95 developed symptomatic disease. If these findings are con-
firmed, they will represent an important public health ad-
vance, and provision of the vaccine candidates would be in 
the interests of many individuals. The FDA may thus grant 
an EUA, making either or both vaccines available before each 
study’s completion and also before FDA marketing approval. 
Some commentators argue that clinical trials are ethically 
acceptable only as long as there is insufficient evidence that 
the intervention offered in one arm is superior to what is of-
fered in another arm, or to what is available outside the trial 
(9). This view implies that it would be unethical to continue 
Pfizer’s and Moderna’s placebo-controlled trials given the 
findings of efficacy. It also implies it would be unethical to 
test other unproven vaccine candidates against placebo. 
Proponents defend this view on the grounds that it pro-
vides a way to protect participants from excessive risks. They 
argue further that researchers conducting clinical trials are 
obligated to treat participants consistent with their clinical 
interests and conclude that it is unethical to give participants 
a placebo once a safe and efficacious vaccine has been iden-
tified. 
We disagree. This view fails to recognize that the obliga-
tions researchers have to their participants are distinct from 
the obligations that clinicians have to their patients (9). It 
further ignores the existence of other mechanisms, including 
independent review and informed consent, to protect re-
search participants from excessive risks. The differences be-
tween the ethics of clinical research and clinical care are 
reflected in the consensus that it can be ethically appropriate 
to invite research participants to accept some risks to collect 
socially valuable data. In particular, codes and guidelines 
around the world permit researchers to expose participants 
in clinical trials, including vaccine trials, to some risks to col-
lect socially valuable data that cannot be obtained in a less 
risky way (10). 
These guidelines have a critical implication for COVID-19 
vaccine trial ethics: Researchers are not obligated to provide 
placebo recipients with a safe and efficacious vaccine once 
one has been identified. Instead, researchers are obligated to 
ensure that any plans to conduct placebo-controlled trials 
remain ethically appropriate given current evidence. Such 
plans must be reviewed and approved by an independent 
board, known as an institutional review board (IRB) in the 
United States, which must find that a number of conditions 
are satisfied (11). Two of these conditions are particularly im-
portant for determining the acceptability of conducting pla-
cebo-controlled trials after a vaccine candidate has been 
found to be safe and efficacious: Is the trial’s risk-benefit pro-
file still acceptable? Do participants consent? 
ACCEPTABLE RISK-BENEFIT PROFILE 
Continuing a blinded, placebo-controlled trial after the vac-
cine candidate being tested has been found to be safe and 
efficacious is justified only when the trial’s risk-benefit pro-
file remains acceptable. Making this determination requires 
answering three questions: (i) What is the social value of con-
tinuing the trial? (ii) What are the risks to participants of con-
tinuing the trial? (iii) Are the risks to participants sufficiently 
low and justified by the social value of continuing the trial? 
Social value 
Continuing a trial after the vaccine candidate has been found 
to be safe and efficacious can provide an opportunity to col-
lect several types of socially valuable data. Most importantly, 
it can provide greater confidence in and a more precise point 
estimate of the vaccine’s efficacy and offer an opportunity to 
collect additional safety data, including data on any uncom-
mon or delayed side effects. It can also help to assess how 
long the vaccine’s protective effect lasts; offer insight into the 
vaccine’s impact in various subgroups, such as older individ-
uals or those with comorbidities; and evaluate whether the 
vaccine candidate protects against infection itself. 
Risks to participants 
Once a vaccine candidate is found to be efficacious, partici-
pants in the placebo arm are known to be at higher risk of 
symptomatic disease than those in the active arm. The degree 
of risk depends on the chances that participants in the pla-
cebo arm will become infected, the risks they face if they are, 
and how much protection the vaccine candidate offers. 
The chances that participants in the placebo arm will be 
infected depends on the local transmission rate, preventive 
measures they adopt, and the amount of time they remain on 
placebo. When participants are on placebo for a short time, 
the chances of infection are correspondingly low. For exam-
ple, Moderna plans to continue its placebo-controlled trial 
until 151 cases of symptomatic disease are identified (5). 
Given current transmission rates, this may take as little as a 
few weeks. 
Remaining on placebo for a few weeks, rather than access-
ing an efficacious vaccine, poses a low chance of substantial 
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poses a low chance of substantial harm to individuals at low 
risk for severe disease. 
Remaining on placebo for an extended period can pose 
considerable risks to individuals at high risk of severe dis-
ease. The extent of these risks depends critically on what op-
tions are available to them. In the setting of few effective 
treatments and potentially strained hospital systems, receiv-
ing placebo for an extended period rather than a safe and ef-
ficacious vaccine can pose substantial risks. However, if high-
risk individuals would not have access to a safe and effica-
cious vaccine outside of research—for example, there is only 
enough supply for the trial or they are not part of a prioritized 
group that will receive the vaccine during the time of the 
trial—receiving placebo in a clinical trial poses few additional 
risks to them. 
Are risks sufficiently low and justified? 
There is no algorithm for determining how much social value 
a given clinical trial has and whether its social value justifies 
the risks participants face. As a result, IRBs tend to focus on 
ensuring that a trial has the potential to collect important 
data and that the risks of substantial harm are low. 
Trials with the potential to collect data helpful for ad-
dressing a global pandemic have considerable social value. 
Inviting competent adults to participate in such trials can be 
ethical when doing so poses a small increase in their risk of 
experiencing substantial harm. This suggests that it can be 
ethically acceptable to continue a placebo-controlled trial for 
a short period after the vaccine candidate has been found to 
be safe and efficacious, even when participants might be able 
to access the vaccine candidate outside the trial, for example, 
through an EUA (12). By contrast, if continuing the trial does 
not offer the opportunity to collect socially valuable data, or 
comparable data can be obtained in less risky ways, continu-
ing the trial with a placebo arm for any length of time would 
be ethically problematic. 
Inviting participants who are at low risk of severe disease 
to remain blinded and stay in the trial for a longer period can 
be acceptable when it offers the potential to collect data that 
might be helpful for addressing the pandemic. In most cases, 
continuing a blinded, placebo-controlled design with high-
risk individuals for longer periods will not yield data of suffi-
cient value to justify it. Exceptions might include when the 
individuals cannot access an efficacious vaccine outside the 
trial and their participation is needed to collect valuable data, 
or they are in a group for whom no efficacious vaccine candi-
date has been identified. Otherwise, individuals at high risk 
of severe disease should be unblinded and those on the pla-
cebo arm offered the vaccine within a redesigned study or 
given the opportunity to seek the vaccine outside the trial. 
When the value of the data to be collected does not justify 
the risks of continuing the trial as designed, researchers have 
several options. They can unblind participants; offer placebo 
recipients the vaccine, possibly as part of an expanded access 
program; and follow them to collect additional data (13). Al-
ternatively, researchers might redesign the trial, for example, 
to include a crossover in which the blind is maintained and 
those on the placebo arm receive the vaccine after they com-
plete the placebo arm. Finally, in some cases, it may make 
sense to simply stop the trial and unblind participants, thus 
allowing those in the placebo arm to seek the vaccine else-
where. 
OTHER TRIALS 
Even when a vaccine candidate is found to be safe and effica-
cious, there are likely to be good reasons to study others. An-
other vaccine candidate might be more effective, generate 
longer-lasting immunity, work better in certain subpopula-
tions, provide greater protection against severe disease, or 
prevent infection better. Other candidates may also be supe-
rior with respect to cost or other practical considerations. For 
example, Pfizer’s vaccine candidate must be stored at very 
low temperatures until 5 days before administration, a re-
quirement which will reduce its availability in many parts of 
the world. 
When there are safe and effective interventions available, 
the default is to use them rather than placebo as the compar-
ator in clinical trials. Thus, if the Pfizer or Moderna vaccine 
candidates, or others, are confirmed to be safe and effica-
cious, researchers should consider whether their trials can be 
redesigned as a comparison between the vaccine candidate 
they are testing and a safe and efficacious vaccine. When 
making this decision, researchers and IRBs should take into 
account that an active comparison trial is likely to require 
larger sample sizes and extend the duration of the trial. 
Redesigning ongoing trials to include an efficacious vac-
cine as an active comparator may not always be feasible or 
valuable. If continuing to evaluate the vaccine candidate 
nonetheless offers important social value, participants at low 
risk of severe disease might be invited to stay blinded and 
remain in the placebo-controlled trial. If continued participa-
tion appreciably increases participants’ risk of severe disease, 
researchers should discuss participants’ options for obtaining 
an efficacious vaccine outside research. 
DISCLOSURE, UNBLINDING, CONSENT 
Researchers are ethically obligated to inform participants of 
developments that might influence their willingness to re-
main in a clinical trial. Clearly, the fact that a vaccine candi-
date has been found to be safe and efficacious meets this 
standard. Hence, investigators should inform participants in 
all trials of such a finding. This information should include 
the vaccine’s safety record, the level of protection it provides, 











First release: 3 December 2020  www.sciencemag.org  (Page numbers not final at time of first release) 4 
efficacious, and whether it might be available through an 
EUA or other means. 
Researchers should then explain the plans for their trial 
going forward and solicit participants’ consent. To minimize 
potential confusion and distrust (14), participants should un-
derstand the rationale behind the plan and that their prior 
consent does not obligate them to continue to participate. If 
researchers intend to continue with a placebo-controlled de-
sign, participants can be encouraged to remain in the trial. 
However, once a safe and efficacious vaccine candidate is 
available, knowing whether they received placebo or vaccine 
becomes relevant to a participant’s decision whether to seek 
the vaccine outside research. Hence, participants who choose 
to leave the trial should be informed whether they received 
the vaccine candidate or placebo. 
If one or more efficacious vaccines become widely availa-
ble outside research, continuing a blinded, placebo-con-
trolled trial might result in participants in both the active and 
placebo arms dropping out and seeking the vaccine else-
where. Researchers should anticipate this possibility and 
consider whether they might unblind participants, offer an 
efficacious vaccine to the placebo recipients, and follow eve-
ryone. Alternatively, it might make sense to continue the 
blinded, placebo-controlled trial with a guarantee that indi-
viduals in the placebo arm will receive an efficacious vaccine 
once their participation in the study is completed. With care-
ful planning and systematic assessment of the social value 
and risks, we believe it can be ethical to conduct some pla-
cebo-controlled trials of vaccine candidates for COVID-19 
even after we have an efficacious vaccine. Doing so may be 
necessary to effectively address a pandemic that is causing so 
much harm around the world. 
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